| 1. |
- Hillier, Ladeana W, et al.
(author)
-
Sequence and comparative analysis of the chicken genome provide unique perspectives on vertebrate evolution
- 2004
-
In: Nature. - 0028-0836 .- 1476-4687. ; 432:7018, s. 695-716
-
Journal article (peer-reviewed)abstract
- We present here a draft genome sequence of the red jungle fowl, Gallus gallus. Because the chicken is a modern descendant of the dinosaurs and the first non-mammalian amniote to have its genome sequenced, the draft sequence of its genome--composed of approximately one billion base pairs of sequence and an estimated 20,000-23,000 genes--provides a new perspective on vertebrate genome evolution, while also improving the annotation of mammalian genomes. For example, the evolutionary distance between chicken and human provides high specificity in detecting functional elements, both non-coding and coding. Notably, many conserved non-coding sequences are far from genes and cannot be assigned to defined functional classes. In coding regions the evolutionary dynamics of protein domains and orthologous groups illustrate processes that distinguish the lineages leading to birds and mammals. The distinctive properties of avian microchromosomes, together with the inferred patterns of conserved synteny, provide additional insights into vertebrate chromosome architecture.
|
|
| 2. |
- Mann, D. L., et al.
(author)
-
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
- 2004
-
In: Circulation. - 1524-4539. ; 109:13, s. 1594-602
-
Journal article (peer-reviewed)abstract
- BACKGROUND: Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept in heart failure. METHODS AND RESULTS: Patients with New York Heart Association class II to IV chronic heart failure and a left ventricular ejection fraction < or =0.30 were enrolled in 2 clinical trials that differed only in the doses of etanercept used. In RECOVER, patients received placebo (n=373) or subcutaneous etanercept in doses of 25 mg every week (n=375) or 25 mg twice per week (n=375). In RENAISSANCE, patients received placebo (n=309), etanercept 25 mg twice per week (n=308), or etanercept 25 mg 3 times per week (n=308). The primary end point of each individual trial was clinical status at 24 weeks. Analysis of the effect of the 2 higher doses of etanercept on the combined outcome of death or hospitalization due to chronic heart failure from the 2 studies was also planned (RENEWAL). On the basis of prespecified stopping rules, both trials were terminated prematurely owing to lack of benefit. Etanercept had no effect on clinical status in RENAISSANCE (P=0.17) or RECOVER (P=0.34) and had no effect on the death or chronic heart failure hospitalization end point in RENEWAL (etanercept to placebo relative risk=1.1, 95% CI 0.91 to 1.33, P=0.33). CONCLUSIONS: The results of RENEWAL rule out a clinically relevant benefit of etanercept on the rate of death or hospitalization due to chronic heart failure.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Green, Dido, et al.
(author)
-
Clinical incidence of sensory integration difficulties in adults with learning disabilities and illustration of management
- 2003
-
In: British Journal of Occupational Therapy. - : Sage Publications. - 0308-0226 .- 1477-6006. ; 66:10, s. 454-463
-
Journal article (peer-reviewed)abstract
- This project investigated the prevalence of sensory processing problems in a clinical group and also examined the clinical effectiveness of a specialised therapeutic technique, sensory integrative therapy (SIT), in the treatment of maladaptive behaviours in two adults with learning disabilities. The Sensory Integration Inventory - Revised for Individuals with Developmental Disabilities (SII-R, Reisman and Hanschu 1992) was used to identify two clients suspected of having poor sensory processing. A single-subject experimental design (ABAB) was used to assist the objective measurement of the effects of SIT. The results suggest that the SII-R has some limitations in identifying clients who would benefit from SIT. One client (Ms D) was seen to instigate more positive interactions with her environment during and following the treatment phases; however, the overhabituated behaviours of the other client (Mr K) showed little response to SIT. These results are discussed in the form of a practitioner's update, with respect to the indicators of sensory processing dysfunction and the potential therapeutic benefits of SIT as an adjunct to therapeutic interventions for individuals with learning disabilities.
|
|
| 6. |
|
|
| 7. |
|
|
